Hemorrhagic occlusive retinal vasculitis leading to the diagnosis of ciliary body melanoma.

Ciliary body Hemorrhagic occlusive retinal vasculitis Intracameral vancomycin Malignant melanoma Plaque radiotherapy Uvea

Journal

Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
ISSN: 1319-4534
Titre abrégé: Saudi J Ophthalmol
Pays: India
ID NLM: 9425601

Informations de publication

Date de publication:
Historique:
received: 29 04 2018
revised: 13 09 2018
accepted: 16 09 2018
entrez: 2 4 2019
pubmed: 2 4 2019
medline: 2 4 2019
Statut: ppublish

Résumé

Hemorrhagic occlusive retinal vasculitis (HORV) is a condition associated with intraocular vancomycin during surgical intervention, most frequently following bilateral sequential cataract surgery. Because of the high rate of ophthalmic vascular complications in this condition, gonioscopic evaluation for identification of neovascularization of the angle and iris is essential. Careful examination can reveal previously asymptomatic and unassociated lesions of the iris or ciliary body. We present the case of a 71-year-old female who was diagnosed with a ciliary body melanoma secondary to complete ophthalmic examination associated with HORV. She reported decreased vision to light perception in the left eye (OS) following sequential, bilateral cataract surgery. Fundus examination OS demonstrated diffuse retinal vasculitis, retinal ischemia, and extensive hemorrhage. Evaluation included inflammatory and coagulopathy laboratory evaluation, carotid ultrasonography and magnetic resonance imaging (MRI) of the brain and orbits, all of which proved unrevealing, except for an enhancing mass OS on MRI. Further evaluation revealed a pigmented mass with features of melanoma in the anterior chamber angle extending into the ciliary body. Fine needle aspiration biopsy revealed high risk cytogenetic characteristics, and plaque radiotherapy was successfully employed.

Identifiants

pubmed: 30930668
doi: 10.1016/j.sjopt.2018.09.004
pii: S1319-4534(18)30147-4
pmc: PMC6424716
doi:

Types de publication

Journal Article

Langues

eng

Pagination

81-83

Subventions

Organisme : NEI NIH HHS
ID : K23 EY030530
Pays : United States
Organisme : NEI NIH HHS
ID : L30 EY029524
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Références

Arch Ophthalmol. 1999 Feb;117(2):170-7
pubmed: 10037560
Arch Ophthalmol. 2009 Aug;127(8):989-98
pubmed: 19667335
Retina. 2012 Sep;32(8):1601-7
pubmed: 22466484
Ophthalmology. 2014 Jan;121(1):269-275
pubmed: 24139123
Ophthalmology. 2017 May;124(5):583-595
pubmed: 28110950
Ophthalmology. 2017 May;124(5):609-618
pubmed: 28159380
Ophthalmology. 2017 Oct;124(10):1523-1531
pubmed: 28495150

Auteurs

Basil K Williams (BK)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

R Joel Welch (R)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Kristen H Nwanyanwu (KH)

Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, USA.

Carol L Shields (CL)

Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.

Classifications MeSH